See more : NHN KCP Corp. (060250.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Lantheus Holdings, Inc. (LNTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantheus Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Corsa Coal Corp. (CRSXF) Income Statement Analysis – Financial Results
- AmBase Corporation (ABCP) Income Statement Analysis – Financial Results
- Delek Group Ltd. (DLEKG.TA) Income Statement Analysis – Financial Results
- Starwin Media Holdings Inc. (SWMD) Income Statement Analysis – Financial Results
- Sproutly Canada Inc. (SPR.CN) Income Statement Analysis – Financial Results
Lantheus Holdings, Inc. (LNTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lantheus.com
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 935.06M | 425.21M | 339.41M | 347.34M | 343.37M | 331.38M | 301.85M | 293.46M | 301.60M | 283.67M | 288.11M | 356.29M |
| Cost of Revenue | 586.89M | 353.36M | 237.51M | 200.65M | 172.53M | 168.49M | 169.24M | 164.07M | 157.94M | 176.08M | 206.31M | 212.91M | 261.08M |
| Gross Profit | 709.54M | 581.70M | 187.70M | 138.76M | 174.81M | 174.89M | 162.14M | 137.78M | 135.52M | 125.52M | 77.36M | 75.20M | 95.22M |
| Gross Profit Ratio | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% | 46.18% | 41.62% | 27.27% | 26.10% | 26.72% |
| Research & Development | 77.71M | 311.68M | 44.97M | 32.79M | 20.02M | 17.07M | 18.13M | 12.20M | 14.36M | 13.67M | 30.46M | 40.60M | 40.95M |
| General & Administrative | 125.46M | 133.58M | 150.40M | 69.27M | 61.24M | 50.17M | 49.84M | 38.83M | 43.89M | 37.31M | 33.04M | 32.52M | 32.86M |
| Selling & Marketing | 141.74M | 100.24M | 68.42M | 40.90M | 41.89M | 43.16M | 42.32M | 36.54M | 34.74M | 35.12M | 35.23M | 37.44M | 38.69M |
| SG&A | 267.19M | 233.83M | 218.82M | 110.17M | 103.13M | 93.33M | 92.16M | 75.37M | 78.63M | 72.43M | 68.26M | 69.96M | 71.55M |
| Other Expenses | 0.00 | -1.70M | -7.35M | 2.20M | -6.22M | 2.47M | 8.64M | 220.00K | -89.00K | 3.00K | 9.25M | 34.80M | 205.00K |
| Operating Expenses | 344.90M | 545.51M | 263.78M | 142.96M | 123.15M | 110.40M | 110.28M | 87.58M | 92.99M | 86.10M | 98.72M | 110.56M | 112.50M |
| Cost & Expenses | 931.79M | 898.87M | 501.30M | 343.61M | 295.68M | 278.89M | 279.53M | 251.65M | 250.93M | 262.18M | 305.03M | 323.47M | 373.57M |
| Interest Income | 19.64M | 2.61M | 45.00K | 238.00K | 686.00K | 167.00K | 18.00K | 0.00 | 24.00K | 27.00K | 104.00K | 252.00K | 333.00K |
| Interest Expense | 20.02M | 7.19M | 7.75M | 9.48M | 13.62M | 17.41M | 18.41M | 26.62M | 38.72M | 42.29M | 42.92M | 42.01M | 37.66M |
| Depreciation & Amortization | 60.04M | 47.93M | 42.29M | 24.69M | 13.38M | 13.86M | 19.14M | 18.26M | 19.65M | 18.25M | 25.16M | 27.40M | 32.76M |
| EBITDA | 491.01M | 81.83M | -25.00M | 22.69M | 55.62M | 80.81M | 77.19M | 73.18M | 46.59M | 58.17M | 7.53M | 26.86M | 17.74M |
| EBITDA Ratio | 37.87% | 3.69% | -19.62% | -0.59% | 13.08% | 19.50% | 18.25% | 16.70% | 14.47% | 19.13% | 4.63% | 9.40% | 4.50% |
| Operating Income | 364.64M | -13.44M | -76.09M | -4.20M | 32.06M | 64.49M | 51.85M | 56.59M | 42.53M | 39.42M | -18.89M | -750.00K | -17.28M |
| Operating Income Ratio | 28.13% | -1.44% | -17.89% | -1.24% | 9.23% | 18.78% | 15.65% | 18.75% | 14.49% | 13.07% | -6.66% | -0.26% | -4.85% |
| Total Other Income/Expenses | 46.30M | -9.48M | -14.21M | -7.28M | -23.03M | -14.94M | -12.21M | -28.29M | -54.31M | -41.78M | -41.65M | -7.19M | -35.90M |
| Income Before Tax | 410.94M | 26.72M | -75.04M | -11.48M | 28.63M | 49.55M | 39.64M | 28.29M | -11.78M | -2.37M | -60.54M | -42.56M | -53.18M |
| Income Before Tax Ratio | 31.70% | 2.86% | -17.65% | -3.38% | 8.24% | 14.43% | 11.96% | 9.37% | -4.01% | -0.78% | -21.34% | -14.77% | -14.92% |
| Income Tax Expense | 84.28M | -1.35M | -3.76M | 1.99M | -3.04M | 9.03M | -83.75M | 1.53M | 2.97M | 1.20M | 1.01M | -555.00K | 84.08M |
| Net Income | 326.66M | 28.07M | -71.28M | -13.47M | 31.67M | 40.52M | 123.39M | 26.76M | -14.75M | -3.56M | -61.56M | -42.00M | -137.26M |
| Net Income Ratio | 25.20% | 3.00% | -16.76% | -3.97% | 9.12% | 11.80% | 37.23% | 8.87% | -5.02% | -1.18% | -21.70% | -14.58% | -38.52% |
| EPS | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 | -0.60 | -0.20 | -3.40 | -2.36 | -7.61 |
| EPS Diluted | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 | -0.60 | -0.20 | -3.34 | -2.32 | -7.61 |
| Weighted Avg Shares Out | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M | 24.44M | 17.81M | 18.08M | 17.79M | 18.03M |
| Weighted Avg Shares Out (Dil) | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.50M | 38.89M | 32.66M | 24.44M | 18.08M | 18.40M | 18.08M | 18.03M |
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates
Lantheus Reports First Quarter 2024 Financial Results
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
Is Lantheus (LNTH) Stock Undervalued Right Now?
Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term
Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?
Source: https://incomestatements.info
Category: Stock Reports